Software innovations from Topcon

Article

Topcon Medical Systems has introduced new OCT mapping software and enhanced its image management system.

Topcon Medical Systems has introduced new OCT mapping software and enhanced its image management system.

The Topcon 3D OCT FastMap, including enhanced analysis protocols, 3D report interface with historical report viewer and connectivity to IMAGEnet, is the next generation of Topcon's TrueMap software. The FastMap software and upgrade package is included in the price of the Topcon 3D OCT-1000 and its warranty.

The EyeRoute Image Management System stores and tracks images, and eliminates the risk of lost images. The first of the new development for the system is the introduction of EyeRoute On Board, which can be loaded on any personal computer to enhance access to the system. EyeRoute Mobile, the second development, allows access to the system from anywhere around the world through any 3G compatible handheld device. An Apple iPhone is supplied as part of the package.

Topcon showcased the new products and features at the meeting of the American Academy of Ophthalmology (AAO).

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
Logos for Topcon Healthcare (left, black and purple) and Intelligent Retinal Imaging Systems (IRIS, right, blue and green). Concept image for diabetic eye disease retina screening company merger. Image courtesy of Topcon Healthcare.

Topcon expands AI portfolio with Intelligent Retinal Imaging Systems acquisition

Hattie Hayes
August 1st 2025
Article

The IRIS is a cloud-based model that supports artificial intelligence-assisted diabetic retinopathy screening

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
August 1st 2025
Podcast
Two people sit at a table. Their hands are visible, as are computers, pencils, notebooks, clipboards and documents. Concept image for business merger, licensing partnership, work collaboration, commercialisation throughout Europe, Re-Vana Therapeutics and Boehringer Ingelheim ocular eye drug therapy. Image credit: ©NAMPIX – stock.adobe.com

Re-Vana Therapeutics and Boehringer Ingelheim announce collaboration, licensing partnership

Lynda Charters
August 1st 2025
Article

The companies will focus their joint effort on extended-release therapies for ocular disease

The retina undergoing fundus imaging. Concept image for retinal imgaging, OCT, CA, cardiac angiography, optical coherence tomography and biomarkers. Image credit: ©Panama – stock.adobe.com

Biomarkers of microvascular retinal perfusion indicating coronary heart disease

Lynda Charters
August 1st 2025
Article

Optical coherence tomography may help identify patients at risk of cardiovascular disease before coronary angiography

A photo of the European Medicines Agency (EMA) headquarters. Concept image for Alteogen aflibercept biosimilar approval, Committee for Medicinal Products for Human Use CHMP positive opinion for EYLUXVI. Image credit: ©Ogulcan Aksoy - SCA – stock.adobe.com

Alteogen receives positive CHMP opinion for aflibercept biosimilar EYLUXVI

Martin David Harp
August 1st 2025
Article

According to the company, the EMA’s opinion was based on the “totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package”

A brain and a fungus mushroom both depicted in illustration. Concept image for fungal infection and diabetic eye disease. Image credit: ©Anson – stock.adobe.com – generated with AI

Fungal infection and vision impact in patients with diabetic eye disease

Lynda Charters
August 1st 2025
Article

Rhino-orbital-cerebral mucormycosis, a life-threatening fungal infection, typically occurs in patients with diabetes

© 2025 MJH Life Sciences

All rights reserved.